Zobrazeno 1 - 10
of 84
pro vyhledávání: '"Gi-Ae Kim"'
Publikováno v:
Clinical and Molecular Hepatology, Vol 30, Iss 4, Pp 793-806 (2024)
Background/Aims Serum hepatitis B virus (HBV) DNA levels and non-invasive liver fibrosis scores are significantly associated with hepatocellular carcinoma (HCC) risk in chronic hepatitis B (CHB) patients. Nonetheless, the relationship between HBV DNA
Externí odkaz:
https://doaj.org/article/99ee7a9021b740b8ad6ab34791fa5418
Publikováno v:
Clinical and Molecular Hepatology, Vol 29, Iss 4, Pp 831-843 (2023)
The existing term non-alcoholic fatty liver disease (NAFLD) has raised substantial concerns due to its inherent disadvantages of using exclusionary diagnostic criteria and the stigmatizing word ‘fatty.’ Three pan-national liver associations set o
Externí odkaz:
https://doaj.org/article/d742d4f0e9b9400c96bbe7d078fa8bd3
Autor:
Yewan Park, Seong-Kyun Na, Jae-Hyun Yoon, Sung-Eun Kim, Ji-Won Park, Gi-Ae Kim, Hyo-Young Lee, Young-Sun Lee, Jeong-Han Kim
Publikováno v:
Medicina, Vol 60, Iss 7, p 1132 (2024)
Background and Objectives: Chronic hepatitis C (CHC) can be cured with direct-acting antiviral (DAA) therapy. In Korea, sofosbuvir (SOF) and ledipasvir (LDV)/SOF were launched in 2016. Patients who achieve a sustained virologic response (SVR) followi
Externí odkaz:
https://doaj.org/article/dc00c24c45bd4ff8a14399e11147bffb
Autor:
Myung Han Hyun, Ji Hoon Kim, Jeong Won Jang, Jeong Eun Song, Do Seon Song, Hye Won Lee, Young Youn Cho, Gi-Ae Kim, Eileen L. Yoon, Dong Hyun Sinn, Soon Sun Kim, Sun Young Yim, Hyun Yang, Jihyun An
Publikováno v:
The Korean Journal of Gastroenterology, Vol 82, Iss 3, Pp 127-136 (2023)
Background/Aims: Chronic hepatitis C is a major risk factor for liver cirrhosis, hepatocellular carcinoma, and hepatic failure. Although traditional practices, including acupuncture, tend to increase the risk of HCV infection, the association remains
Externí odkaz:
https://doaj.org/article/1963cd99cba545cca8c9c3df43e72f30
Publikováno v:
The Korean Journal of Internal Medicine, Vol 38, Iss 3, Pp 338-348 (2023)
Background/Aims Chronic hepatitis C (CHC) is the second leading cause of liver-related mortality and is more prevalent in the elderly population in Korea. Decisions to initiate treatment and selection of proper antiviral agents may be challenging amo
Externí odkaz:
https://doaj.org/article/85910d28342f43f881f0b395386a382b
Publikováno v:
Liver Cancer, Pp 1-1 (2023)
Introduction: This study aimed to investigate the liver-related outcomes of newly suggested metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD with increased alcohol intake (MetALD), as well as alcohol-associated liver disease
Externí odkaz:
https://doaj.org/article/e730f324d287431ab3ad5e23da1ed3c4
Autor:
Jae-Hyun Yoon, Sung-Eun Kim, Su-Hyeon Cho, Gi-Ae Kim, Yewan Park, Ji-Won Park, Seong-Hee Kang, Young-Sun Lee, Jeong-Han Kim
Publikováno v:
Medicina, Vol 59, Iss 8, p 1436 (2023)
Aim and Objectives: Direct-acting antiviral (DAA) therapy can cure chronic hepatitis C (CHC), and daclatasvir (DCV)/asunaprevir (ASV) was the first interferon-free DAA therapy introduced in Korea. Patients who achieve sustained virologic response (SV
Externí odkaz:
https://doaj.org/article/05e270036e4c4b45a782e5f300e3778f
Autor:
Gi-Ae Kim, Hyun Chin Cho, Soung Won Jeong, Bo-Kyeong Kang, Mimi Kim, Seungwon Jung, Jungwook Hwang, Eileen L. Yoon, Dae Won Jun
Publikováno v:
Pharmaceuticals, Vol 16, Iss 4, p 623 (2023)
Preclinical data have shown that the herbal extract, ALS-L1023, from Melissa officinalis reduces visceral fat and hepatic steatosis. We aimed to assess the safety and efficacy of ALS-L1023 as the treatment of non-alcoholic fatty liver disease (NAFLD)
Externí odkaz:
https://doaj.org/article/c51eb93ea36344e1b2b07da34e91efbb
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 10 (2022)
BACKGROUND It is unclear whether the level of serum hepatitis B virus (HBV) DNA at baseline affects the on-treatment risk of hepatocellular carcinoma (HCC) in hepatitis B e antigen–positive (HBeAg-positive), noncirrhotic patients with chronic hepat
Externí odkaz:
https://doaj.org/article/edcd3e3d89c14d3c81c25bce13b96001
Publikováno v:
Cancer Medicine, Vol 9, Iss 20, Pp 7781-7791 (2020)
Abstract Background Regular clinic follow‐up is a prerequisite for optimal antiviral therapy and surveillance of hepatocellular carcinoma in patients with chronic hepatitis B (CHB). However, adherence to regular follow‐up stays low in practice. T
Externí odkaz:
https://doaj.org/article/e5f039a130774c2ba0017a4bd55f96be